Ushio (6925) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
9 Sep, 2026Executive summary
Q1 FY2024 net sales decreased 4.4% year-over-year to ¥37.5 billion, with operating profit down 83.3% to ¥0.3 billion and profit attributable to owners down 83.4% to ¥0.2 billion, but results exceeded internal targets after adjusting for one-time costs.
Comprehensive income dropped 54.4% year-over-year to ¥7,311 million, reflecting challenging market and currency conditions.
Business selection, prioritization, and ongoing growth investments supported performance.
Share buybacks are progressing, with about 20% completed as of July 31, 2024.
Financial highlights
Gross profit declined to ¥13,965 million from ¥14,488 million year-over-year.
Ordinary profit decreased 48.4% year-over-year to ¥1,459 million.
EPS fell to ¥2.92, down 81.0% year-over-year.
Operating margin was 0.9%, down from 5.2% a year earlier.
Total assets increased to ¥339,337 million, while net assets decreased to ¥235,253 million, with an equity ratio of 69.3%.
Outlook and guidance
FY2024 forecasts remain unchanged: net sales ¥175.0 billion, operating profit ¥5.0 billion, EPS ¥46.79.
Anticipate recovery in lithography equipment sales and semiconductor market from H2 FY2024.
Dividend floor set at ¥70 per share for FY2024–FY2026.
Latest events from Ushio
- Net sales grew 0.8% but profits fell sharply; full-year profit outlook revised upward.6925
Q2 2025 - Profits and sales fell but exceeded forecasts; dividend and buybacks increased.6925
Q3 2025 - Operating profit dropped 32% on lower sales and inventory write-downs, but cash flow improved.6925
Q4 2025 - Net loss despite higher sales, with lamp business acquisition to support future growth.6925
Q1 2026 - Profits and sales declined YoY, but cash flow and select segment earnings improved.6925
Q2 2026 - Profits and sales rose, with strong Visual Imaging gains and a positive FY2026 outlook.6925
Q4 2026 - Operating profit rose despite lower sales, with strong gains in Visual Imaging and Life Sciences.6925
Q3 2026